Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NewLink Genetics
Biotech
NewLink wields ax as it chases leaner IDO program
NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing.
Phil Taylor
Aug 1, 2018 10:38am
ASCO: Don’t write off IDO yet, says NewLink
Jun 4, 2018 3:22pm
Roche pens death notice for NewLink IDO/TDO cancer collaboration
May 15, 2018 9:32am
Bristol-Myers drops phase 3 trials of $800M IDO drug
May 1, 2018 7:56am
AstraZeneca, NewLink pen PD-L1 and IDO combination pact
Sep 25, 2017 9:50am
Roche ditches work on NewLink’s IDO cancer candidate
Jun 8, 2017 7:50am
